Is it feasible to stop venetoclax/venetoclax every 28 days?

Venetoclax/Venetoclax, as an innovative targeted therapy drug, is widely used to treat malignant hematological diseases such as chronic lymphocytic leukemia. Its mechanism of action is to specifically bind to B-cell lymphoma factor 2 (BCL-2), thereby blocking the anti-apoptotic effect of BCL-2 and promoting tumor cells to undergo apoptosis. However, the dosing strategy for venetoclax is not set in stone and must be tailored based on each patient's specific condition and the doctor's clinical judgment.

As for the proposal of “stopping medication every 28 days” is not a definite and feasible solution. The treatment plan for Veneclast is highly individualized and depends on the patient's disease type, severity of illness, overall health, and tolerance and response to the drug. Therefore, this periodic discontinuation pattern may not be suitable for all patients.

In actual treatment, the administration frequency and dosage of Veneclat are carefully designed by doctors based on the patient's real-time condition and feedback. Typically, venetoclax is taken continuously, once daily, until the desired therapeutic effect is achieved or side effects that are intolerable to the patient occur. It is important to note that the therapeutic effects of venetoclax require continued drug exposure, and frequent drug discontinuation may interfere with the treatment process.

In addition, possible side effects of venetoclax, such as thrombocytopenia and neutropenia, need to be considered. These are factors that must be weighed when formulating a medication plan. Therefore, patients should pay close attention to their physical condition during treatment and promptly report any discomfort or abnormalities to their doctor.